{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:23:40Z","timestamp":1790702620629,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2021CFB382"],"award-info":[{"award-number":["2021CFB382"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2021CFB382"],"award-info":[{"award-number":["2021CFB382"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Small subcortical infarction (SSI) accounts for approximately 25% of ischemic strokes and shares a comparable recurrence rate of cardiovascular events with other stroke subtypes. This study aimed to evaluate the efficacy and safety of various antiplatelet for secondary prevention of SSI by network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched Medline, Embase, Cochrane Library, and Web of Science from inception to October 2024 for randomized controlled trials (RCTs). Efficacy outcomes included: incidence of major adverse cardiovascular events (MACEs), rates of any stroke and ischemic stroke recurrence. Safety outcomes included: incidence of intracranial hemorrhage, severe bleeding, any bleeding events, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>A total of 24 RCTs involving 47,507 SSI patients were included in systematic review. The NMA included 19 RCTs (39,137 patients). The NMA demonstrated that Cilostazol showed the best efficacy in preventing MACEs (surface under the cumulative ranking curve (SUCRA): 90.0%). cilostazol significantly reduced the incidence of MACEs compared to aspirin (OR, 0.66; 95% CI, 0.49\u20130.89), ticlopidine (OR, 0.65; 95% CI, 0.43\u20131.00), dipyridamole (OR, 0.61; 95% CI, 0.42\u20130.90), vorapaxar (OR, 0.51; 95% CI, 0.35\u20130.74), Sarpogrelate (OR, 0.62; 95% CI, 0.40\u20130.97), and placebo (OR, 0.51; 95% CI, 0.37\u20130.71). Regarding safety, aspirin plus clopidogrel and vorapaxar was associated with a significantly increased risk of severe bleeding events compared to the control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions:<\/jats:title>\n                    <jats:p>Cilostazol may be the most effective agent for preventing cardiovascular event recurrence. Aspirin plus clopidogrel and vorapaxar may be not recommended due to heightened bleeding risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>International prospective register of systematic reviews (PROSPERO) - CRD42024607819<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873251331470","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:35:51Z","timestamp":1744385751000},"page":"1233-1245","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"given":"Xiao","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyong","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6670-7352","authenticated-orcid":false,"given":"Tong","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-791X","authenticated-orcid":false,"given":"Wenhao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026012115064819100_bibr1-23969873251331470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/ijs.12352","article-title":"Acute diffusion-weighted imaging lesion patterns predict progressive small subcortical infarct in the perforator territory of the middle cerebral artery","volume":"10","author":"Duan","year":"2015","journal-title":"Int J Stroke"},{"key":"2026012115064819100_bibr2-23969873251331470","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.bj.2022.03.014","article-title":"Evaluation of clinical relevance and underlying pathology for hemodynamic compromise in acute small subcortical infarction using MRI-based neuroimaging markers","volume":"46","author":"Pan","year":"2023","journal-title":"Biomed J"},{"key":"2026012115064819100_bibr3-23969873251331470","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/01.STR.0000079818.08343.8C","article-title":"Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies","volume":"34","author":"Schulz","year":"2003","journal-title":"Stroke"},{"key":"2026012115064819100_bibr4-23969873251331470","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/ene.14593","article-title":"Baseline white matter hyperintensities affect the course of cognitive function after small vessel disease-related stroke: a prospective observational study","volume":"28","author":"Fruhwirth","year":"2021","journal-title":"Eur J Neurol"},{"key":"2026012115064819100_bibr5-23969873251331470","first-page":"161","article-title":"Rontal signs following subcortical infarction","volume":"29","author":"Corbett","year":"1992","journal-title":"Clin Exp Neurol"},{"key":"2026012115064819100_bibr6-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012661","article-title":"Early neurologic deterioration in Lacunar Stroke: clinical and imaging predictors and association with long-term outcome","volume":"97","author":"Vynckier","year":"2021","journal-title":"Neurology"},{"key":"2026012115064819100_bibr7-23969873251331470","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/23969873211062019","article-title":"Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischaemic stroke: A cohort study","volume":"7","author":"Portegijs","year":"2022","journal-title":"Eur Stroke J"},{"key":"2026012115064819100_bibr8-23969873251331470","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/01.STR.27.5.842","article-title":"Functional outcome in patients with lacunar infarction","volume":"27","author":"Samuelsson","year":"1996","journal-title":"Stroke"},{"key":"2026012115064819100_bibr9-23969873251331470","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/STROKEAHA.110.599464","article-title":"Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis","volume":"41","author":"Nah","year":"2010","journal-title":"Stroke"},{"key":"2026012115064819100_bibr10-23969873251331470","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/STROKEAHA.114.008422","article-title":"Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials","volume":"46","author":"Kwok","year":"2015","journal-title":"Stroke"},{"key":"2026012115064819100_bibr11-23969873251331470","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades","year":"2024","journal-title":"Res Synth Methods"},{"key":"2026012115064819100_bibr12-23969873251331470","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00228-022-03413-z","article-title":"Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis","volume":"79","author":"Hou","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012115064819100_bibr13-23969873251331470","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026012115064819100_bibr14-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2026012115064819100_bibr15-23969873251331470","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2026012115064819100_bibr16-23969873251331470","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"2026012115064819100_bibr17-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2026012115064819100_bibr18-23969873251331470","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026012115064819100_bibr19-23969873251331470","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: the Lacunar Intervention Trial-2 (LACI-2) randomized clinical trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026012115064819100_bibr20-23969873251331470","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/STROKEAHA.122.039900","article-title":"Dual antiplatelet therapy with cilostazol for secondary prevention in lacunar stroke: subanalysis of the CSPS.com Trial","volume":"54","author":"Nishiyama","year":"2023","journal-title":"Stroke"},{"key":"2026012115064819100_bibr21-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206775","article-title":"Genotype-guided dual antiplatelet therapy in minor stroke or transient ischemic attack with a single small subcortical infarction","volume":"100","author":"Liu","year":"2023","journal-title":"Neurology"},{"key":"2026012115064819100_bibr22-23969873251331470","doi-asserted-by":"crossref","first-page":"631220","DOI":"10.3389\/fneur.2021.631220","article-title":"Clopidogrel plus aspirin in patients with different types of single small subcortical infarction","volume":"12","author":"Wang","year":"2021","journal-title":"Front Neurol"},{"key":"2026012115064819100_bibr23-23969873251331470","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.02.009","article-title":"Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial","volume":"22","author":"Shimizu","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026012115064819100_bibr24-23969873251331470","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"2026012115064819100_bibr25-23969873251331470","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000338247","article-title":"Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Han","year":"2013","journal-title":"Eur Neurol"},{"key":"2026012115064819100_bibr26-23969873251331470","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012115064819100_bibr27-23969873251331470","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"2026012115064819100_bibr28-23969873251331470","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012115064819100_bibr29-23969873251331470","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00415-009-5035-4","article-title":"The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials","volume":"256","author":"Uchiyama","year":"2009","journal-title":"J Neurol"},{"key":"2026012115064819100_bibr30-23969873251331470","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012115064819100_bibr31-23969873251331470","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"2026012115064819100_bibr32-23969873251331470","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/01.STR.0000195045.40409.85","article-title":"Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2","volume":"37","author":"Ariesen","year":"2006","journal-title":"Stroke"},{"key":"2026012115064819100_bibr33-23969873251331470","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2005.09.003","article-title":"Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study","volume":"6","author":"Matsumoto","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"2026012115064819100_bibr34-23969873251331470","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"2026012115064819100_bibr35-23969873251331470","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"2026012115064819100_bibr36-23969873251331470","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"2026012115064819100_bibr37-23969873251331470","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\u201cAICLA\u201d controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"key":"2026012115064819100_bibr38-23969873251331470","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","volume":"349","author":"International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","year":"1997","journal-title":"Lancet"},{"key":"2026012115064819100_bibr39-23969873251331470","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","volume":"349","author":"Chen ZM; CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke","year":"1997","journal-title":"Lancet"},{"key":"2026012115064819100_bibr40-23969873251331470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5551\/jat.56093","article-title":"Efficacy and safety of prasugrel by stroke subtype: a sub-analysis of the PRASTRO-I randomized controlled trial","volume":"28","author":"Kitazono","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"2026012115064819100_bibr41-23969873251331470","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"2026012115064819100_bibr42-23969873251331470","first-page":"123","article-title":"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","volume":"4","author":"Cavallari","year":"2011","journal-title":"Pharmgenomics Pers Med"},{"key":"2026012115064819100_bibr43-23969873251331470","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel-drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012115064819100_bibr44-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001652","article-title":"CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study","volume":"4","author":"McDonough","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026012115064819100_bibr45-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100573","article-title":"CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel","volume":"2","author":"Magavern","year":"2023","journal-title":"JACC Adv"},{"key":"2026012115064819100_bibr46-23969873251331470","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/pgs-2020-0198","article-title":"Dosage optimization of clopidogrel via a precision medicine approach: the way forward","volume":"23","author":"Aswathy","year":"2022","journal-title":"Pharmacogenomics"},{"key":"2026012115064819100_bibr47-23969873251331470","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873251331470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873251331470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/4\/1233\/65869521\/23969873251331470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/4\/1233\/65869521\/23969873251331470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:08:18Z","timestamp":1769026098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/4\/1233\/8377196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873251331470","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,1]]},"published":{"date-parts":[[2025,12,1]]}}}